Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
CRXT was delisted on the 30th of August, 2022.
13 hedge funds and large institutions have $3.73M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
8% more funds holding
Funds holding: 12 → 13 (+1)
64% less capital invested
Capital invested by funds: $10.5M → $3.73M (-$6.73M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$114K |
| 2 |
Millennium Management
New York
|
+$49.8K |
| 3 |
Renaissance Technologies
New York
|
+$44.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$26.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$4.69M |
| 2 |
PIA
Powell Investment Advisors
Miami,
Florida
|
-$156K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$51K |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$44K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$31K |
CRXT Hedge Fund Activity: Q1 2022 in Review
13 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q1 2022, worth a combined $3.73M — down 64% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRXT positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $114K. The largest seller was Armistice Capital, exiting entirely with an estimated $4.69M sold.
- 13 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q1 2022, up from 12 in Q4 2021.
- Funds reported $3.73M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q1 2022, down 64% quarter-over-quarter.
- 7 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q1 2022 and 6 closed out, a net change of +1 holder.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q1 2022 was Bridgeway Capital Management, an estimated $114K added.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q1 2022 was Armistice Capital, an estimated $4.69M sold.
Based on aggregated 13F filings for Q1 2022.